David Kyle, MD
Family Medicine · Anderson, SCNPI 1952370728
Payments from drug & device makers
Across 343 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$721
- Novo Nordisk$643
- Pfizer$592
- AstraZeneca$576
- Lilly USA, LLC$485
- Bayer$295
- plus $3K from 29 others
What the payments were for
- Food & beverage$5,926100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 45 | $721 |
| Novo Nordisk | 45 | $643 |
| Pfizer | 36 | $592 |
| AstraZeneca | 24 | $576 |
| Lilly USA, LLC | 32 | $485 |
| Bayer | 17 | $295 |
| Novartis | 14 | $288 |
| Teva Pharmaceuticals USA, Inc. | 12 | $211 |
| Boehringer Ingelheim | 11 | $203 |
| Johnson & Johnson | 10 | $200 |
| Amgen | 15 | $198 |
| Dexcom, Inc. | 10 | $162 |
| Edwards Lifesciences | 5 | $148 |
| GSK | 8 | $121 |
| Xeris Pharmaceuticals, Inc. | 6 | $100 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $100 |
| Merck | 6 | $93 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $92 |
| Esperion Therapeutics, Inc. | 5 | $89 |
| Antares Pharma, Inc. | 5 | $84 |
| Idorsia Pharmaceuticals US Inc | 4 | $72 |
| Abbott | 4 | $61 |
| Exact Sciences | 4 | $59 |
| Halozyme Inc | 3 | $49 |
| Phathom Pharmaceuticals, Inc. | 3 | $44 |
| Verity Pharmaceuticals Inc. | 2 | $43 |
| Vibrant Gastro, Inc. | 1 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Intuitive Surgical | 1 | $26 |
| Clarus Therapeutics Inc. | 2 | $25 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Cranial Technologies, Inc | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $18 |
| Insmed, Inc. | 1 | $16 |
How this compares
$5,938 in reported general payments places this provider in the 85th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 165 | $158,318 |
| MounjaroTirzepatide | 122 | $127,178 |
| OzempicSemaglutide | 54 | $69,300 |
| FarxigaDapagliflozin Propanediol | 45 | $40,655 |
| EliquisApixaban | 56 | $36,636 |
| Repatha SureclickEvolocumab | 48 | $31,318 |
| QuliptaAtogepant | 11 | $20,769 |
| LinzessLinaclotide | 24 | $19,282 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $19,125 |
| TrulicityDulaglutide | 13 | $18,994 |
| XareltoRivaroxaban | 27 | $16,779 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $13,512 |
| MyrbetriqMirabegron | 15 | $9,199 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $6,375 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $6,049 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat | $203 | $171,830181 claims |
| Lilly USA, LLCMounjaro, Trulicity | $485 | $146,172135 claims |
| Novo NordiskOzempic | $643 | $69,30054 claims |
| AstraZenecaFarxiga, Brilinta | $576 | $45,54056 claims |
| AbbVieQulipta, Linzess, Synthroid | $721 | $43,13867 claims |
| PfizerEliquis | $592 | $36,63656 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $121 | $25,50046 claims |
| Johnson & JohnsonXarelto | $200 | $16,77927 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $9,19915 claims |
| MerckSteglatro | $93 | $4,07812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Anderson
- Erin CookseyAnderson$1.2M
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.